['hiv-1-infection']
['genvoya 150mg-150mg-200mg-10mg tablet', 'dolutegravir 50 mg plus one rti']

        Inclusion Criteria:

          1. Age >18 years

          2. Willing and able to provide informed consent

          3. On a stable (at least 3 months) antiretroviral therapy with DTG 50 mg QD plus one RTI

          4. HIV-RNA <50 copies/mL since at least 6 months

        Exclusion Criteria:

          1. Active AIDS-defining condition (except Kaposi's sarcoma non requiring systemic
             chemotherapy)

          2. Serious illness requiring systemic treatment and/or hospitalization

          3. Current use of immunomodulant or immunosuppressive drugs

          4. Need (or will likely need) of treatment with antacids

          5. Use of drugs contraindicated with study drugs, according to technical sheets

          6. Previous suboptimal therapies with NRTIs or presence of TAMs (type 1 or 2) in previous
             resistance tests (patients with the 184I/V mutation alone are allowed to enter the
             study)

          7. Resistance or previous virological failure to InSTIs

          8. Detectable HCV-RNA

          9. Documented allergy to COBI or EVG or FTC or tenofovir.

         10. Absolute neutrophil count (ANC) <500/µL

         11. Haemoglobin <8.0 g/dL

         12. Platelet count <50,000/µL

         13. eGFR <30 mL/min/1.73m2 by CKD-EPI equation

         14. Alanine aminotransferase (ALT) more than 5 times the upper limit of normal (ULN)

         15. Presence of Child Pugh Class B or C liver cirrhosis.

         16. Pregnancy or breastfeeding

         17. Woman of childbearing potential who does not agree to adopt highly effective
             contraception.
      